Javle, Milind

Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial

Shroff, R. T., Javle, M. M., Xiao, L., Kaseb, A. O., Varadhachary, G. R., Wolff, R. A., Raghav, K. P. S., Iwasaki, M., Masci, P., Ramanathan, R. K., et al. (2019) · JAMA Oncology

Cholangiocarcinoma and Gallbladder Cancer StudiesPediatric Hepatobiliary Diseases and Treatments

Cited by 468

Phase II Trial of Cetuximab, Gemcitabine, and Oxaliplatin Followed by Chemoradiation With Cetuximab for Locally Advanced (T4) Pancreatic Adenocarcinoma: Correlation of Smad4(Dpc4) Immunostaining With Pattern of Disease Progression

Crane, C. H., Varadhachary, G. R., Yordy, J. S., Staerkel, G. A., Javle, M. M., Safran, H., Haque, W., Hobbs, B. D., Krishnan, S., Fleming, J. B., et al. (2011) · Journal of Clinical Oncology

Pancreatic and Hepatic Oncology ResearchPancreatitis Pathology and Treatment

Cited by 288

Transport properties of pancreatic cancer describe gemcitabine delivery and response

Koay, E. J., Truty, M. J., Cristini, V., Thomas, R. M., Chen, R., Chatterjee, D., Kang, Y., Bhosale, P. R., Tamm, E. P., Crane, C. H., et al. (2014) · Journal of Clinical Investigation

Pancreatic and Hepatic Oncology ResearchMRI in cancer diagnosis

Cited by 184

Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies

Javle, M. M., Shroff, R. T., Xiong, H., Varadhachary, G. A., Fogelman, D., Reddy, S. A., Davis, D., Zhang, Y., Wolff, R. A., & Abbruzzese, J. L. (2010) · BMC Cancer

PI3K/AKT/mTOR signaling in cancerPancreatic and Hepatic Oncology Research

Cited by 170

Olaparib Monotherapy for Previously Treated Pancreatic Cancer With DNA Damage Repair Genetic Alterations Other Than Germline BRCA Variants: Findings From 2 Phase 2 Nonrandomized Clinical Trials

Javle, M., Shacham-Shmueli, E., Xiao, L., Varadhachary, G., Halpern, N., Fogelman, D., Boursi, B., Uruba, S., Margalit, O., Wolff, R. A., et al. (2021) · JAMA Oncology

PARP inhibition in cancer therapyPancreatic and Hepatic Oncology Research

Cited by 127

Association of clinical factors with a major pathologic response following preoperative therapy for pancreatic ductal adenocarcinoma

Cloyd, J. M., Wang, H., Egger, M. E., Tzeng, C.-W. D., Prakash, L. R., Maitra, A., Varadhachary, G. R., Shroff, R., Javle, M., Fogelman, D., et al. (2017) · JAMA Surgery

Pancreatic and Hepatic Oncology ResearchCholangiocarcinoma and Gallbladder Cancer Studies

Cited by 112

A Visually Apparent and Quantifiable CT Imaging Feature Identifies Biophysical Subtypes of Pancreatic Ductal Adenocarcinoma

Koay, E. J., Lee, Y., Cristini, V., Lowengrub, J. S., Kang, Y., Lucas, F. A. S., Hobbs, B. P., Ye, R., Elganainy, D., Almahariq, M., et al. (2018) · Clinical Cancer Research

Pancreatic and Hepatic Oncology ResearchRadiomics and Machine Learning in Medical Imaging

Cited by 110

Single-cell sequencing reveals trajectory of tumor-infiltrating lymphocyte states in pancreatic cancer

Schalck, A., Sakellariou-Thompson, D., Forget, M.-A., Sei, E., Hughes, T. G., Reuben, A., Bai, S., Hu, M., Kumar, T., Hurd, M. W., et al. (2022) · Cancer Discovery

Cancer Immunotherapy and BiomarkersPancreatic and Hepatic Oncology Research

Cited by 85

Inactivation of tumor suppressor gene pten in early and advanced gallbladder cancer

Roa, I., de Toro, G., Fernández, F., Game, A., Muñoz, S., de Aretxabala, X., & Javle, M. (2015) · Diagnostic Pathology

Cholangiocarcinoma and Gallbladder Cancer StudiesGallbladder and Bile Duct Disorders

Cited by 22

Genomic classification of clinically advanced pancreatic ductal adenocarcinoma (PDAC) based on methylthioadenosine phosphorylase (MTAP) genomic loss (MTAP loss).

Ngoi, N., Scholefield, E. L., Parini, V., Huang, R. S. P., Janovitz, T., Danziger, N., Levy, M. A., Pant, S., Javle, M. M., Ross, J. S., et al. (2022) · Journal of Clinical Oncology

Pancreatic and Hepatic Oncology ResearchCancer Genomics and Diagnostics

Cited by 7